Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors

JAMA Netw Open. 2021 Mar 1;4(3):e211839. doi: 10.1001/jamanetworkopen.2021.1839.

Author

Kartik Sehgal^{1

2}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.

PMID: 33760084
DOI: 10.1001/jamanetworkopen.2021.1839

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Disease Progression
Humans
Immune Checkpoint Inhibitors
Incidence
Neoplasms* / drug therapy

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors